<p><b>TABLE OF INTERACTIONS WITH</b></p>

<p><b>ANTI-TNF ALPHA </b></p>

<p><b>From the French ANSM drug interactions document of September 2016, p. 30</b></p>

<table cellspacing="0" cellpadding="0" border="1">
<tbody>
<tr>
<td valign="top"><p><b>ANTI-TNF ALPHA</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>LO4AB</b></p></td>
<td valign="top"><p><b>ABATACEPT </b></p>

<p><b>RxNorm: 614391</b></p>

<p><b>ATC: L04AA24 </b></p></td>
<td valign="top"><p>Increase of the immunodepression </p></td>
<td valign="top"><p><b>Not recommended</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>ANTI-TNF ALPHA</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>LO4AB</b></p></td>
<td valign="top"><p><b>ANAKINRA</b></p>

<p><b>RxNorm: 72435 </b></p>

<p><b>ATC: L04AC03</b></p></td>
<td valign="top"><p>Increased risk of serious infections and neutropenia</p></td>
<td valign="top"><p><b>Not recommended</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>ANTI-TNF ALPHA</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>LO4AB</b></p></td>
<td valign="top"><p><b>CANAKINUMAB</b></p>

<p><b>RxNorm: 853491</b></p>

<p><b>ATC: L04AC08</b></p></td>
<td valign="top"><p>Risk of increase of serious infections</p></td>
<td valign="top"><p><b>Not recommended</b></p></td>
</tr>

<tr>
<td valign="top"><p><b>ANTI-TNF ALPHA</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>LO4AB</b></p></td>
<td valign="top"><p><b>ATTENUATED LIVE VIRUS VACCINES</b></p>

<p><b>CLASS CODE: </b></p>

<p><b>J07B-001</b></p></td>
<td valign="top"><p>Risk of general vaccine disease possibly fatal</p></td>
<td valign="top"><p><b>CONTRAINDICATION</b></p>

<p>And during the 3 months following the end of the treatment.</p></td>
</tr>

</tbody>
</table>

